| Vol. 10.10 – 15 March, 2022 |
| |
|
|
| Investigators evaluated the activity of pembrolizumab in classic and endemic Kaposi sarcoma with cutaneous extension requiring systemic treatment. [Lancet Oncology] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers generated an epigenetic and transcriptional atlas of T cell differentiation from healthy humans that included exhausted CD8 T cells and applied this resource in three ways. [Immunity] |
|
|
|
| Although PD-1 and TIGIT were thought to regulate different costimulatory receptors, effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. [Immunity] |
|
|
|
| Scientists reported that tumor-derived Jagged1 is a key regulator of the tumor immune microenvironment. Jagged1 promoted tumorigenesis in multiple spontaneous mammary tumor models. [Cell Reports] |
|
|
|
| Large cohorts of non-small cell lung cancer patients from The Cancer Genome Atlas and a single-cell sequencing dataset were integrated to illustrate immunosuppressive phenotypes of tumor-associated macrophages, followed by experimental verification. [Cancer Immunology Immunotherapy] |
|
|
|
| Researchers showed that PRMT5 drove allergic airway inflammation in a mouse model reproducing multiple aspects of human severe asthma. [Journal of Immunology] |
|
|
|
| Pyroptosis regulation patterns were comprehensively evaluated on 33 pyroptosis-related genes in 1716 glioma samples. The correlations were analyzed between pyroptosis regulation patterns and tumor microenvironmentimmune cell infiltration properties. [Discover Oncology] |
|
|
|
| The authors compared immune cell populations, inflammatory and anti-inflammatory cytokine in the serum, and monocyte and T cell functional activity using umbilical cord samples from neonates with known opioid exposure during gestation and from control neonates without known exposure. [Pediatric Research] |
|
|
|
| Investigators demonstrated that BCOR and BCORL1 mutations in leukemia unlinked PRC1.1 repressive function from target genes, resulting in epigenetic reprogramming and activation of aberrant cell signaling programs that mediated treatment resistance. [Blood Cancer Discovery] |
|
|
|
|
| The authors discuss recent studies on the involvement of gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis along with human omics data to provide prospective insights into future prevention and treatment of Inflammatory bowel disease and colorectal cancer. [Cell Host & Microbe] |
|
|
|
| Previous studies have shown that T cells play a key role both in the central nervous system and in the periphery, leading to a profound imbalance in the immune network of Parkinson’s Disease patients. [Journal of Parkinsons Disease] |
|
|
|
|
| PDS Biotechnology Corporation announced that the National Cancer Institute achieved the intended enrollment objective in the Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV-associated cancers. [PDS Biotechnology Corporation] |
|
|
|
| Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. [Imugene] |
|
|
|
|
| April 4 – 8, 2022 Saint Malo, France |
|
|
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| University of Sherbrooke – Sherbrooke, Quebec, Canada |
|
|
|
| Amsterdam UMC – Amsterdam, Netherlands |
|
|
|
| BioNTech – Gaithersburg, Maryland, United States |
|
|
|
| National Institute for Health and Medical Research – Paris, France |
|
|
|
|